Proposed Escalation Strategy A theoretical cagrilintide and retatrutide combination protocol might follow this gradual escalation approach: Weeks 1-4: Foundation Phase Cagrilintide: 0.6 mg weekly Retatrutide: 2 mg weekly Focus: Establishing tolerance to both compounds Monitoring: Gastrointestinal effects, appetite changes Weeks 5-8: Escalation Phase Cagrilintide: 1.2 mg weekly Retatrutide: 4 mg weekly Focus: Increasing receptor activation Monitoring: Weight changes, metabolic markers Weeks 9-12: Optimization Phase Cagrilintide: 2.4 mg weekly Retatrutide: 8 mg weekly Focus: Approaching therapeutic targets Monitoring: Comprehensive metabolic assessment Weeks 13+: Maintenance Phase Cagrilintide: 3.0-4.5 mg weekly Retatrutide: 8-12 mg weekly Focus: Sustained metabolic effects Monitoring: Long-term safety and efficacy This graduated approach mirrors the successful strategies used in cagrilintide 10mg research protocols, where slow escalation minimizes side effects while building therapeutic benefit
Vukojevic et al., 2018), while counteracting prolonged bleeding and thrombocytopenia (Stupnisek et al., 2012
The tables below cover injectable protocols from 1mg to 3mg daily, topical applications from 0.5% to 4% concentration, and reconstitution calculations for both 50mg and 100mg vials
Round up for priming losses, dropped syringes, damaged swabs, and any protocol adjustments
But weight loss percentages only tell part of the story
